Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Drug Studies Placed on FDA Hold

09/17/2021 | 05:36am EDT

By Matt Grossman

Protagonist Therapeutics Inc.'s clinical studies for its rusfertide drug have been placed on a clinical hold by the U.S. Food and Drug Administration because of a recent finding in a mouse-model study, the company said Friday.

Benign and malignant skin tumors were observed in the mouse-model study, Protagonist said.

Dosing of patients has been put on hold, the Newark, Calif.-based pharmaceutical company said. Rusfertide was being tested in three Phase 2 trials, to treat polycthemia vera--a type of blood caner--and hereditary hemochromatosis, or iron overload.

Protagonist said it will work with the FDA to make any necessary updates to study protocols.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

09-17-21 0736ET

All news about PROTAGONIST THERAPEUTICS, INC.
10/13PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/12PROTAGONIST THERAPEUTICS : Shares Drop on Elevated Volume
MT
10/12PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/12WALL STREET STOCK EXCHANGE : It's just a period of market normalization
10/12PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $..
MT
10/12PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From N..
MT
10/12PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
10/12ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex...
10/11Health Care Stocks Sliding in Late Monday Trading
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 14,2 M - -
Net income 2021 -117 M - -
Net cash 2021 250 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Capitalization 1 412 M 1 412 M -
EV / Sales 2021 81,6x
EV / Sales 2022 28,3x
Nbr of Employees 101
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | PTGX | US74366E1029 | MarketScreener
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 29,69 $
Average target price 58,29 $
Spread / Average Target 96,3%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.47.27%1 412
MODERNA, INC.219.34%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.99%47 608
SEAGEN INC.-0.54%31 287
CELLTRION, INC.-39.28%24 952